Engage:BDR year-on-year revenues tracking well

Published 27-APR-2020 12:02 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

engage:BDR (ASX:EN1; EN1O) has provided an unaudited trading update in relation to its interim April 2020 financial performance with a comparative analysis relative to the previous corresponding period in 2019.

EN1 has just received the US government Paycheck Protection Program (PPP) funding of $690,000 (US$435,000).

This funding is entirely forgivable and creates no liability for EN1 within 60 days if used entirely on US employees’ payroll.

PPP funding qualification criteria did not require EN1 to prove financial hardship, and the program was strictly for US small businesses with US resident employees.

The program paid for 2.5 months of payroll, with some restrictions (caps on executive pay, etc) and required the funds to be used exclusively on payroll of these employees, entirely forgiven within 60 days.

The net impact to EN1’s balance sheet adds $690,000 to working capital and assets, without any incremental liabilities.

Management expects additional PPP funding in the near future, as the US government has approved and extended the program, currently doubling the initial budget.

As US quarantines continue, management expects the US government to continue deploying funding to small businesses.

EN1’s cash balance is $2.4 million, which is significantly higher than the average cash balance of $1.4 million in 2019 and the 2019 ending cash balance of $1.8 million.

The following table shows the group’s significant outperformance compared with the previous corresponding period, including an improvement in gross profit margins from 38% to 41%.

Revenue building after quarantine leads to subdued start

April 2020 revenue started lighter than expected due to brand budget pauses throughout the US because of the quarantine orders across 85% of the country.

This coupled with the start of a new quarter has resulted in lighter revenues temporarily.

Revenue is expected to continue to increase throughout the balance of the month and greater through subsequent months of the second quarter.

Daily revenue analysis shows an increase of more than 25% over the past 7 days, and management expects revenue to continue to normalise over the balance of the month and into May.

Based on EN1’s average gross profit margins, PPP funding is similar to incremental revenues of $1.65 million.

Management took measures in early March to defer and significantly reduce all operating expense categories to limit cash outflow.

All vendors, partners, and companies EN1 works with have been very malleable, and management expects business to continue as usual.

There have been across-the-board reductions in operating expenditure, including board and director compensation.

Alto, the company’s primary lender, has proactively and voluntarily deferred recent amortisation payments.

During the quarter there were payments of $250,666 associated with executive and non-executive fees paid to director's fees for the March 2020 quarter.

Management anticipates EN1’s industry diversification will work in its favour in terms of weathering the COVID-19 storm.

As the US economy reopens, management expects advertising activity to ramp up.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X